TY - JOUR
T1 - Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders
T2 - A multicenter-observational study
AU - Acciavatti, Tiziano
AU - Lupi, Matteo
AU - Santacroce, Rita
AU - Aguglia, Andrea
AU - Attademo, Luigi
AU - Bandini, Laura
AU - Ciambrone, Paola
AU - Lisi, Giulia
AU - Migliarese, Giovanni
AU - Pinna, Federica
AU - Quattrone, Diego
AU - Ribolsi, Michele
AU - Signorelli, Maria Salvina
AU - Calò, Salvatore
AU - Schifano, Fabrizio
AU - di Giannantonio, Massimo
AU - Martinotti, Giovanni
N1 - © 2017 John Wiley & Sons, Ltd. This is the peer reviewed version of the following article: Acciavatti, T, Lupi, M, Santacroce, R, et al. Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter‐observational study. Hum Psychopharmacol Clin Exp. 2017; 32:e2578. which has been published in final form at https://doi.org/10.1002/hup.2578. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
PY - 2017/5
Y1 - 2017/5
N2 - OBJECTIVE: Comorbidities between psychiatric diseases and use of traditional substances of abuse are common. Nevertheless, there are few data regarding the use of novel psychoactive substances (NPS) among psychiatric patients. Aim of this multicentre survey is to investigate the consumption of a number of psychoactive substances in a young psychiatric sample.METHODS: Between December 2013 and September 2015, a questionnaire was administered in 10 Italian psychiatric care facilities to a sample of 671 patients, aged 18-26 (mean age 22.24; SD 2.87).RESULTS: About 8.2% of the sample declared to have used NPS at least once, and 2.2% had consumed NPS in the previous 3 months. The three psychiatric diagnoses most frequently associated with NPS use were bipolar disorder (23.1%), personality disorders (11.8%), and schizophrenia and related disorders (11.6%). In univariate regression analysis, bipolar disorder was positively associated with NPS consumption, an association that did not reach statistical significance in the multivariate analysis.CONCLUSIONS: The use of NPS in a young psychiatric population appears to be frequent, and probably still underestimated. Bipolar disorder shows an association with NPS use. Careful and constant monitoring and an accurate evaluation of possible clinical effects related to NPS use are necessary.
AB - OBJECTIVE: Comorbidities between psychiatric diseases and use of traditional substances of abuse are common. Nevertheless, there are few data regarding the use of novel psychoactive substances (NPS) among psychiatric patients. Aim of this multicentre survey is to investigate the consumption of a number of psychoactive substances in a young psychiatric sample.METHODS: Between December 2013 and September 2015, a questionnaire was administered in 10 Italian psychiatric care facilities to a sample of 671 patients, aged 18-26 (mean age 22.24; SD 2.87).RESULTS: About 8.2% of the sample declared to have used NPS at least once, and 2.2% had consumed NPS in the previous 3 months. The three psychiatric diagnoses most frequently associated with NPS use were bipolar disorder (23.1%), personality disorders (11.8%), and schizophrenia and related disorders (11.6%). In univariate regression analysis, bipolar disorder was positively associated with NPS consumption, an association that did not reach statistical significance in the multivariate analysis.CONCLUSIONS: The use of NPS in a young psychiatric population appears to be frequent, and probably still underestimated. Bipolar disorder shows an association with NPS use. Careful and constant monitoring and an accurate evaluation of possible clinical effects related to NPS use are necessary.
KW - novel psychoactive substances
KW - bipolar disorder
KW - Dual diagnosis
KW - Binge drinking
KW - young adults
U2 - 10.1002/hup.2578
DO - 10.1002/hup.2578
M3 - Article
C2 - 28517032
SN - 0885-6222
VL - 32
JO - Human Psychopharmacology: Clinical and Experimental
JF - Human Psychopharmacology: Clinical and Experimental
IS - 3
M1 - e2578
ER -